Gradient_Filter.png

Barcode Nanotech
Next Generation Therapeutics

Tag & Track* Technology for Precise Target-Site Location

Generating and screening 1000s of different nanoparticle delivery vehicles

Huge need for RNA/DNA next generation therapeutic delivery vehicles

RNA-based COVID 19 vaccines and the approval of CRISPR clinical trials have changed the regulatory paradigm and drive an unprecedented growth in the lipid-nanoparticle delivery field. We are developing new DNA and RNA - based medications together with the delivery vehicles which lead these next generation therapeutics to their desired cell targets.

Our team generates and in vivo   screens thousands of different barcoded nanoparticles to lead RNA/DNA therapeutics  to desired target sites.

Our technology is protected by 4 distinct IP families, covering screening and identification of particles with different payloads.

Nanoparticles_Distribution.png
THE PROBLEM
While new RNA and DNA therapeutics are being developed, nanoparticle-based delivery vehicles to target these molecules to specific cells are still limited.

Nanoparticle screening is currently limited as a large number of variables can affect the bio-distribution of these delivery vehicles. These variables include: size, lipid composition, surface charge, ligand selection and more.

OUR SOLUTION
Tag & Track* Technology for Precise Target-Site Location

Providing a solution for drug delivery and identification of precise target site location.

Scientist Using Microscope
ABOUT US
Founded in 2017, Barcode has developed and in vivo screened  barcoded nanoparticles as delivery tools for different therapeutics.

We integrate state-of-the-art advances in lipid nanoparticle technologies as drug delivery tools, with formulation screening, tissue analysis and AI, to generate the next generation of RNA and DNA-based therapies. 

ABOUT US
Our scientific and research team

Barcode nanotech's management & researchers and scientists.

pass Ronen BW.jpg
CEO AND CO-FOUNDER
Ronen Eavri, Ph.D. MBA

Leading new product development in pharmaceutical and medical device companies for over 10 years (formally: J&J and D-Pharm) .

Scientific education from the Hebrew University, Technion and MIT.

Annie Sabbah photo
CTO AND CO-FOUNDER
Annie Sabbah, Ph.D.

Former CTO of MPT Diagnostics and Lab Research Manager at Rambam Campus (Technion). Expert in microparticles and molecular biology.

Scientific education from the Technion.

Felix Badinter photo
R&D TEAM LEADER
Felix Badinter M.Sc.

M.Sc. in Biotechnology from the Technion. 


Over 8 years of industrial experience in Research and Development in the fields of biotech and nanotechnology.

Valeria Rukhman photo
ANALITICAL CHEMISTRY LEAD
Valeria Rukhman Ph.D.

Ph.D. in Biochemistry from the faculty of Chemistry of the Technion. 


Over 15 years of experience in pharmaceutical QC laboratories. 

WhatsApp Image 2021-10-19 at 20.52.23.jpeg
SCIENTIST
Or Rosen M.Sc.

M.Sc. in Biotechnology from the Tel-Hai.


Experienced in various chemical and biological processes.

Let's talk.

Barcode nanotech is raising capital and looking to partner with pharma companies for further research.